EPAVANCE for IBD

Formulated for the dietary management of IBD.

Inflammatory bowel disease creates specific nutritional challenges. EPAVANCE addresses the one most relevant to omega‑3: poor absorption of standard fish-oil supplements in an inflamed gut.

Shop EPAVANCE Download the clinician brief

Understanding IBD

IBD affects absorption, not just inflammation.

Crohn's disease and ulcerative colitis (UC) are chronic inflammatory conditions affecting the gastrointestinal tract. Beyond the immediate symptoms, both conditions can compromise nutrient absorption — particularly in active flares, and in areas of the gut affected by disease.

Standard fish-oil supplements use the ethyl ester form of EPA — a molecular structure that requires pancreatic enzyme conversion before absorption. In an inflamed or compromised gut, this conversion step is less reliable. EPAVANCE bypasses the problem by using EPA already in triglyceride form.

  • Affects up to 500,000 people in the UK
  • Crohn's disease can affect any part of the GI tract
  • UC is confined to the colon and rectum
  • Both are associated with chronic, relapsing inflammation
Diagram showing gastrointestinal absorption pathway

The Role of EPA

EPA and the resolution of inflammation.

EPA as a substrate

EPA is a precursor to specialised pro-resolving mediators (SPMs) — molecules involved in the natural resolution of inflammation. Maintaining adequate EPA levels supports the body's own inflammatory resolution pathways.

Triglyceride bioavailability

rTG-form EPA is absorbed via the same pathway as dietary fat — without requiring enzymatic conversion. This makes it more reliably absorbed than ethyl ester EPA, particularly in the setting of GI inflammation.

FSMP classification

EPAVANCE's classification as a Food for Special Medical Purposes reflects the specific dietary management need it addresses. The FSMP category exists precisely for conditions like IBD where standard dietary intake is insufficient.

Person managing IBD dietary routine at home

Who EPAVANCE is for

For adults with IBD, under clinician guidance.

EPAVANCE is indicated for the dietary management of gastrointestinal inflammation associated with IBD in adults. It is designed to be used alongside, not instead of, existing IBD therapy — and should be started under the guidance of a gastroenterologist, dietitian or GP.

Not suitable for:
  • · Children under 18
  • · Those allergic to fish or fish products
  • · Use as a sole source of nutrition
  • · Anyone not under medical supervision for IBD
View dosage guidance

Common questions

What patients ask us.

Yes. EPAVANCE is indicated for the dietary management of gastrointestinal inflammation associated with IBD, which includes both Crohn's disease and ulcerative colitis. Individual suitability should be confirmed with your gastroenterologist.
EPAVANCE can be taken during remission as part of ongoing dietary management. Some patients and clinicians use it as a maintenance strategy. Discuss the appropriate duration and dose with your HCP.
No. EPAVANCE is a dietary management product, not a medicine. It is designed to be used alongside your prescribed IBD therapy, not as a replacement. Never adjust your medication without consulting your gastroenterologist.
EPAVANCE is a dietary management product, not a fast-acting therapeutic. Most patients who use it do so as part of a long-term dietary strategy. Your clinician is best placed to discuss realistic expectations for your specific situation.
EPAVANCE is generally well-tolerated, but during a significant flare your clinical team may adjust your overall dietary plan. Always consult your gastroenterologist before starting or continuing any dietary intervention during a flare.

Still have a question? Speak to our patient team →

Available now

Ready to start?

EPAVANCE is available direct, delivered to your door. Subscribe and save 13%, or try a single pack.

Subscribe — £34 / month One-time purchase — £39
Free UK delivery Cancel anytime 60-day returns